GovTrack.us

 
Bookmark and Share
S. 30:
HOPE Act
110th Congress

This is a bill in the U.S. Congress originating in the Senate ("S."). A bill must be passed by both the Senate and House and then be signed by the President before it becomes law.

Bill numbers restart from 1 every two years. Each two-year cycle is called a session of Congress. This bill was created in the 110th Congress, in 2007-2008.

The titles of bills are written by the bill's sponsor and are a part of the legislation itself. GovTrack does not editorialize bill summaries.

2007-2008

Summaries

Highlights from Project Vote Smart

The following is Project Vote Smart's highlights for this bill, generously made available by PVS:

  • The following summary was for the Passage for this bill on 2007-04-11. The bill may have changed since then.
  • - Amends the Public Health Service Act (42 U.S.C. 289 et seq.) so that research is conducted without the destruction, discarding, or risk of injury to other human embryos by using only stem cells that are naturally dead (Sec 3)
  • - Creates a joint study between the Secretary of Health and Human Services and the Institute of Medicine to recommend a plan for an amniotic and placental stem cell bank program, and to maximize research potentials such as the collection and storage of stem cells, standards setting, information sharing, distribution reimbursement, research, and outcome measures (Sec 4)
  • Congressional Research Service Summary

    The following summary was written by the Congressional Research Service, a well-respected nonpartisan arm of the Library of Congress. GovTrack did not write and has no control over these summaries.

    4/11/2007--Passed Senate without amendment. (This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.) Hope Offered through Principled and Ethical Stem Cell Research Act or the HOPE Act -
    Section 3 -
    Amends the Public Health Service Act to require the Secretary of Health and Human Services to develop techniques for the isolation, derivation, production, or testing of stem cells, including pluripotent stem cells that have the flexibility of embryonic stem cells (whether or not they have an embryonic source), that may result in improved understanding of or treatments for diseases and other adverse health conditions, provided that such techniques do not involve: (1) the creation of a human embryo or embryos for research purposes; or (2) the destruction or discarding of, or risk of injury to, a human embryo of embryos other than those that are naturally dead. Requires the Secretary to: (1) provide guidance concerning the next steps required for additional research; (2) prioritize research with the greatest potential for near-term clinical benefits; (3) take into account techniques outlined by the President's Council on Bioethics and any other appropriate techniques and research; and (4) require assurances from grant applicants, in the case of research involving stem cells from a naturally dead embryo, that no alteration of the timing, methods, or procedures used to create, maintain, or intervene in the development of a human embryo was made solely for the purpose of deriving the stem cells. Sets forth reporting requirements. Authorizes appropriations.
    Section 4 -
    Directs the Secretary to enter into a contract with the Institute of Medicine to conduct a study to: (1) recommend an optimal structure for an amniotic and placental stem cell bank program; and (2) address pertinent issues to maximize the potential of such technology.

    Because the U.S. Congress posts most legislative information online one legislative day after events occur, GovTrack is usually one legislative day behind. For more information about where this data comes from, see About GovTrack.us.
    To cite this information, click a citation format for a suggestion: APA | MLA | Wikipedia Template.